Cost-effectiveness comparison of cabozantinib with everolimus, axitinib, and nivolumab in the treatment of advanced renal cell carcinoma following the failure of prior therapy in England

PURPOSE: The aim of this study was to compare the cost-effectiveness of cabozantinib with the standard of care in England in adult patients with advanced renal cell carcinoma (aRCC), following prior vascular endothelial growth factor receptor (VEGFR)-targeted therapy. METHODS: We developed a partiti...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clinicoecon Outcomes Res
Autors principals: Meng, Jie, Lister, Johanna, Vataire, Anne-Lise, Casciano, Roman, Dinet, Jerome
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2018
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5922245/
https://ncbi.nlm.nih.gov/pubmed/29719414
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S159833
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars